Connect with us

Press Release

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Published

2 months ago

on

Raleigh, United States, August 31st, 2026, FinanceWire

Executes a major step in RedHill’s strategic roadmap to fundamentally reposition the Company’s commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability

—

Realizes substantial value from RedHill’s 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill’s transformational commercial expansion

—

Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments

 

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the divestment of its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) (“Apotex”) for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones.

“This transaction is a pivotal milestone for RedHill. We are converting our 70% stake in Talicia into immediate capital, significantly stronger liquidity and meaningful potential upside, while fully funding the next major step in our commercial business expansion. I want to thank the RedHill team for developing and positioning this important product for success, targeting H. pylori infection, the main cause of gastric cancer and stomach ulcers,” said Dror Ben-Asher, RedHill’s Chief Executive Officer. “We are confident that given its proven capabilities, Apotex is the right home to grow Talicia globally. We thank Apotex for their partnership on the successful conclusion of this transaction, which unlocks the resources needed to scale RedHill’s existing gastrointestinal (GI) commercial franchise into a stronger and larger one, including new, high-value, FDA-approved product opportunities intended to drive sustained growth and accelerate our path toward operational profitability.”

Under the terms of the agreement, RedHill received $18 million in cash and has the potential to receive up to an additional $35 million in payments based on worldwide net sales milestones from Apotex. In return, Apotex will receive RedHill’s 70% interest in Talicia, following Apotex’s prior acquisition of Cumberland Pharmaceuticals Inc.’s U.S. branded business, which included Cumberland Pharmaceuticals Inc.’s 30% ownership in Talicia.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About RedHill Biopharma  

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), an ongoing Phase 2 study in prostate cancer in combination with darolutamide and a Phase 2/3 program for hospitalized COVID-19; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

About Apotex 

Apotex is a Canadian-based global health company. Apotex improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Apotex is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of that sale; the Company’s ability to acquire or develop new products, expected revenue growth, the Company’s anticipated path toward operational profitability, and the Company’s strategic plans for its commercial business. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the divestment of Talicia does not result in any planned asset acquisitions, or that any such acquisitions are not commercially successful; the risk that proceeds from the transaction are insufficient to fund the Company’s strategic plans or that such plans do not achieve the anticipated results; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn’s disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company’s ability to regain and maintain compliance with Nasdaq’s listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements, including under the Apotex agreement, or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company’s proposed development plans for its programs; the risk that the Company’s development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) the Company’s ability to collect on its judgement against Kukbo; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Contact

Chief Corporate & BD Officer
Adi Frish
RedHill Biopharma
adi@redhillbio.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

More Than 25,000 Companies Met With Post Oak Group in Q3 2026, Just 47 Secured Representation

Published

15 hours ago

on

October 19, 2026

By

Post Oak Group reported that more than 25,000 companies met with the firm in Q3 2026 to explore advisory relationships, yet only 47 were formally engaged, an acceptance rate of less than 0.19%. The figure is up only slightly from 45 engagements in Q2, reflecting the firm’s deliberate choice to keep strict acceptance standards rather than scale its client roster with demand.

Houston, Texas, United States, 19th Oct 2026 – The extent of Post Oak Group’s selectivity is perhaps best illustrated by the firm’s third-quarter 2026 engagement figures.

During Q3 2026 alone, more than 25,000 companies met with Post Oak Group to explore potential advisory relationships. Of those, just 47 matters were formally engaged by the firm, representing an acceptance rate of less than 0.19%.

The 47 engagements represent only a modest increase from the 45 matters formally engaged during the second quarter of 2026. However, while the number of accepted mandates has remained relatively consistent, the volume of prospective companies meeting with the firm has increased dramatically.

This widening disparity between prospective client demand and actual engagement volume reflects a deliberate decision by Post Oak Group to maintain stringent acceptance standards rather than expand its mandate portfolio in proportion to market demand.

“We have experienced tremendous growth in the number of companies seeking our representation, but that does not mean we intend to take on substantially more clients,” said Alex Treistman, Managing Partner at Post Oak Group. “We believe we are the best in the business at what we do, and maintaining that standard requires discipline. Our resources are finite, regardless of the size of our organization, and we reserve those resources for the highest-quality companies that we believe are best positioned to attract investment from our network.”

At the center of the firm’s selective engagement strategy is its extensive network of angel investors, family offices, venture capital firms, and other private capital providers. These relationships, developed and maintained through years of institutional investor coverage, represent one of Post Oak Group’s most valuable strategic assets.

The firm maintains that its responsibility extends beyond the companies it represents to the investors who rely on Post Oak Group to identify and introduce compelling private market opportunities.

“We have a responsibility to our investors to ensure that the companies we bring to them are of exceptional quality,” said Karan Ramchandani, Head of Capital Markets at Post Oak Group. “Our network includes some extraordinarily sophisticated angels, family offices, and venture capital firms. These are relationships we take very seriously. We are not going to compromise the integrity of that network simply because another company is willing to pay us an engagement fee.”

According to the firm, its internal evaluation process considers the strength of a prospective client’s management team, business model, financial performance, market opportunity, capital requirements, and overall investment merits.

Equally important is the firm’s conviction that it can deliver meaningful value through its existing investor relationships and transaction execution capabilities.

The result is a highly selective advisory platform in which fewer than one in every 500 companies that met with Post Oak Group during the third quarter ultimately secured formal representation.

For companies that successfully complete the firm’s evaluation process, Post Oak Group believes this selectivity translates into an exceptional level of institutional attention, transaction preparation, investor coverage, and ongoing advisory support.

“Our clients are not competing with thousands of other mandates for our attention,” Treistman added. “When we accept an engagement, that company receives a level of commitment and service that we believe is virtually unmatched in this industry. That is only possible because we are willing to turn away the overwhelming majority of opportunities presented to us.”

Looking ahead, Post Oak Group expects demand for its capital markets advisory services to remain substantial. Nevertheless, the firm has indicated that future growth in prospective client inquiries will not necessarily translate into a corresponding increase in accepted engagements.

Instead, management intends to preserve its selective approach, prioritizing the quality of represented companies, the integrity of its investor relationships, and the depth of service delivered to each client.

“Our goal is not to become the investment bank with the most clients,” Treistman concluded. “Our goal is to be the investment bank that the highest-quality companies want representing them and that the most sophisticated investors trust to bring them opportunities. Everything else is secondary.”

 

About Post Oak Group

Post Oak Group, named the Best Middle-Market Investment Bank in Texas and the most connected firm to family offices and VC globally, is a Houston-based firm with approximately 300 professionals and more than $82 billion in transactions advised. The firm specializes in mergers and acquisitions and capital markets advisory, advising business owners, entrepreneurs, growth-stage companies, and institutional clients on sell-side transactions, private placements, growth capital financings, and other strategic financial initiatives.

Through its established network of private equity firms, family offices, venture capital firms, angel investors, institutional investors, and strategic acquirers, Post Oak Group focuses on connecting companies with qualified capital partners and delivering relationship-driven investment banking services. With relationships spanning corporate development teams, family offices, and venture-backed buyers across North America, Europe, Australia, Latin America, and select Asian markets, the firm brings a global reach to every engagement.

Media Contact

Organization: Post Oak Group

Contact Person: David Chua

Website: https://www.postoakgroup.co/

Email:
info@postoakgroup.co

City: Houston

State: Texas

Country: United States

Release id: 50029

View source version on King Newswire:
More Than 25,000 Companies Met With Post Oak Group in Q3 2026, Just 47 Secured Representation

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Easy Title Searches Highlights Florida Title Search and Foreclosure Property Research Through EasyTitleSearches.com

Published

15 hours ago

on

October 19, 2026

By

Online resource focuses on comprehensive Florida title searches, property ownership records, foreclosure title searches, property lien searches, mortgage and deed research, judgment searches, lis pendens searches, and real estate due diligence across all 67 Florida counties. Easy Title Searches provides information relevant to residential and commercial property title research, foreclosure auction title searches, pre-foreclosure property investigations, recorded encumbrances, ownership verification, and foreclosure property records, helping homebuyers, real estate investors, attorneys, lenders, and real estate professionals better understand potential title issues, outstanding liens, and property-related risks before purchasing or investing in Florida real estate.

St. Augustine, FL, United States, 19th Oct 2026 – Easy Title Searches is highlighting EasyTitleSearches.com as an online resource focused on Florida property title research, foreclosure records and real estate due diligence. The website brings attention to the importance of reviewing recorded property information before purchasing, financing or investing in Florida real estate.

A Florida title search can help buyers and property professionals identify deeds, mortgages, liens, judgments and other recorded documents that may affect a real estate transaction. Whether evaluating a conventional purchase or a foreclosure opportunity, researching a property’s history can help identify matters requiring further investigation.

Understanding Florida Property Title Searches

Property title research typically involves reviewing documents filed in public records to better understand a parcel’s recorded ownership history and associated interests. A property title search may include deeds, mortgage recordings, liens, easements, judgments and other instruments relevant to a transaction.

Florida property records are maintained through recording systems in the state’s 67 counties. Because document availability and indexing practices vary by jurisdiction, researching an ownership history may require reviewing more than one source. A property ownership search and property deed search can provide starting points for understanding recorded transfers and identifying gaps or questions that merit attention.

Foreclosure Title Searches and Auction Due Diligence

Foreclosure sales can introduce legal and financial complexities that differ from an ordinary home purchase. A Florida foreclosure title search may identify recorded mortgages, judgments, ownership interests and other documents associated with a property involved in foreclosure proceedings.

Before bidding, investors may undertake a foreclosure auction title search and broader foreclosure property search to better understand the record history and locate matters that warrant additional review. This research can complement a review of court proceedings, sale terms and other publicly available information.

Importantly, a foreclosure sale does not necessarily eliminate every lien or obligation. The treatment of recorded interests may depend on lien priority, the foreclosure action and applicable law. Thorough foreclosure due diligence in Florida may therefore require legal review in addition to record research.

Florida Lien Searches, Mortgages and Judgments

Recorded liens can affect the financing, ownership or transfer of a property. A Florida lien search may help identify mortgage liens, judgment liens and other recorded claims that deserve further investigation. A foreclosure lien search can be especially relevant when reviewing a distressed property or auction opportunity.

Some obligations are not fully reflected in a conventional county recording search. Municipal matters, certain assessments and association-related issues may require separate inquiries. A foreclosure mortgage search or review of recorded judgments is one component of broader property due diligence, not a guarantee that every potential issue has been identified.

Lis Pendens and Pre-Foreclosure Property Research

A lis pendens is a recorded notice associated with certain legal proceedings that may affect interests in real estate. A Florida lis pendens search can help researchers locate relevant notices and identify proceedings that may require closer examination.

For investors considering a property before a scheduled auction, a pre-foreclosure property search may involve reviewing ownership transfers, recorded mortgages, foreclosure filings and related court records. These documents can help frame additional questions about a property, although interpreting their legal effect may require qualified professional advice.

A Focused Online Destination for Florida Real Estate Research

Homebuyers, property investors, attorneys, lenders and real estate professionals frequently rely on Florida property records as part of evaluating real estate transactions. Understanding what recorded documents show, and what they do not show, can support more informed decisions and more targeted follow-up research.

Easy Title Searches focuses on these research topics through its online presence, including title investigations, foreclosure documentation and recorded property interests. The website serves as a dedicated point of reference for people seeking information about Florida real estate title research.

About Easy Title Searches

Easy Title Searches is an online resource focused on Florida title searches, foreclosure title research, property ownership records, lien information, mortgage documentation and real estate due diligence.

Media Contact

Organization: Easy Title Searches

Contact Person: Mikey Tyburczy

Website: https://easytitlesearches.com

Email:
mtyb@easytitlesearches.com

Contact Number: +19048066857

City: St. Augustine

State: FL

Country: United States

Release id: 49998

View source version on King Newswire:
Easy Title Searches Highlights Florida Title Search and Foreclosure Property Research Through EasyTitleSearches.com

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

PrimeXBT Launches 14-Day VIP Welcome Offer, Cutting Trading Costs for All New Users

Published

15 hours ago

on

October 19, 2026

By

Castries, Saint Lucia, October 19th, 2026, FinanceWire

PrimeXBT, a global multi-asset broker and crypto asset service provider, has introduced a new VIP Welcome offer, giving all new clients automatic VIP4-tier status for their first 14 days. Activated upon registration with no additional action required, the offer provides immediate access to lower trading costs and enhanced conditions without first meeting the usual trading-volume requirements.

During the welcome period, clients receive 15% discount on Forex and CFD spreads on broker’s PXTrader 2.0 platform, with further reductions of up to 50% on Gold and Bitcoin CFD spreads. VIP4 tier also includes 33% off Crypto Futures taker fees, 10% off Exchange spreads, 24/7 priority support and access to 10% cashback on eligible trading costs through the Rewards Center. Trading volume on MT5 counts towards VIP qualification, but VIP fee and spread discounts only apply on PXTrader 2.0.

PrimeXBT’s VIP Tiers program offers five levels of progressively lower fees and enhanced conditions, with VIP status normally earned based on trading volume over the previous 30 days. Tier upgrades are automatic, and traders can track their progress in real time. The VIP Welcome offer gives all new clients immediate access to VIP 4 without first meeting these volume requirements. After the 14-day welcome period, clients who meet the relevant thresholds can maintain VIP 4 or progress to VIP 5.

“Small differences in spreads and fees can be easy to overlook on a single trade, but they add up over time and can have a substantial impact on costs, particularly for high-volume traders,” said Jonatan Randin, Senior Market Analyst at PrimeXBT. “The VIP Welcome offer gives new clients the opportunity to experience our premium trading conditions from day one, alongside the charting and risk-management tools they need to plan and manage their positions.”

The launch builds on PrimeXBT’s focus on reducing trading costs across key markets. PXTrader 2.0 offers commission-free CFD trading, with EUR/USD spreads from 0 pips. VIP conditions include spreads from $0.17 on Gold, 0.2 points on US500, 0.4 points on NASDAQ and $19 on BTC CFDs at the highest tier. Clients can also unlock VIP tiers using their Rewards Center balance, earned through tasks and trading milestones. The balance can also be used for cashback or trading bonus.

PrimeXBT continues to strengthen its position in multi-asset trading through competitive pricing and professional tools. The VIP Welcome offer reinforces this priority, making market-leading trading conditions accessible to everyone from the very first trade.

To learn more, users can visit PrimeXBT website.

About PrimeXBT

PrimeXBT is a global multi-asset broker and crypto asset service provider trusted by traders in more than 150 countries. The platform bridges traditional and digital markets within one integrated environment, redefining versatility and innovation in online trading. Clients can access Forex, CFDs on indices, commodities, shares, crypto, and Crypto Futures, as well as buy, store and exchange cryptocurrencies. This unified experience extends across both the native PXTrader 2.0 platform and MetaTrader 5, supported by advanced risk-management tools and a wide range of funding options in crypto, fiat and local payment methods. Since 2018, PrimeXBT has focused on empowering traders through broad multi-asset access, fair and transparent conditions, professional-grade technology and dedicated human support. By combining expertise, trust and a client-first approach, PrimeXBT sets a benchmark of excellence in the financial industry and provides traders with the tools they need to trade, grow and succeed with confidence.

Disclaimer: The content provided here is for informational purposes only and is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results. The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money. The Company does not accept clients from the Restricted Jurisdictions as indicated on its website / T&Cs. Some products and services, including MT5, may not be available in your jurisdiction. The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

Contact

PrimeXBT
pr@primexbt.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us